Navigation Links
Genetic Engineering & Biotechnology News reports on advances in miRNA
Date:2/29/2008

New Rochelle, NY, February 29, 2008 miRNA research is now one of the most interesting areas in the life science world, reports Genetic Engineering and Biotechnology News (GEN). Scientists around the globe are studying the effects of over- or underexpression of specific miRNAs on the development and inhibition of pathogenesis in a variety of diseases, according to an article titled miRNA-Regulated Pathways in the March 1 issue of GEN (http://www.genengnews.com/articles/chitem.aspx?aid=2382).

The appeal of miRNA technology lies in its promise and broad applicability across a wide spectrum of biotechnology and medical research, notes John Sterling, Editor-in-Chief of GEN. Increasing numbers of studies are focusing on conditions such as cancer, heart disease, and neurological disorders as well as on aging.

As more miRNAs are identified, researchers are correlating changes in miRNA levels with disease processes. For instance, scientists at the Wistar Institute recently identified miR-373 and miR-520c. Members of the same miRNA family, both were shown to promote tumor metastasis.

Also covered in the GEN article on miRNAs is research taking place at Asuragen, the University of Louisville, IBM, University of Texas Southwestern, Mira Therapeutics, and miRagen Therapeutics. In addition, GEN looks at the latest technologies and services from miRNA research enabling companies such as Exiqon, Sigma-Aldrich, Mirus Bio, Thermo Fisher Scientific, SuperArray Bioscience, and LC Sciences.


'/>"/>

Contact: John Sterling
jsterling@genengnews.com
Mary Ann Liebert, Inc./Genetic Engineering News
Source:Eurekalert

Page: 1

Related biology news :

1. Does the desire to consume alcohol and tobacco come from our genetic makeup?
2. Diverse genetic abnormalities lead to NF-κB activation in multiple myeloma
3. Many parents at-risk for cancer disclose genetic test results to children
4. Genetics determine optimal drug dose of common anticoagulant
5. Claims of sex-related differences in genetic association studies often not properly validated
6. American College of Medical Genetics responds to new FDA labeling decision for warfarin
7. UNC study questions FDA genetic-screening guidelines for cancer drug
8. Genome study shines light on genetic link to height
9. Selexis Announces Advanced Approach to Maximize Power of Genetic Elements for Rapid Development of High Performance Cell Lines
10. Genes, Environment and Health Initiative invests in genetic studies, environmental monitoring
11. Rutgers Genetics receives $7.8 million for autism research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/3/2017)... , April 3, 2017  Data captured ... engineering platform, detected a statistically significant association ... prior to treatment and objective response of ... potential to predict whether cancer patients will ... treatment, as well as to improve both pre-infusion ...
(Date:3/30/2017)... The research team of The Hong Kong ... identification by adopting ground breaking 3D fingerprint minutiae recovery and matching ... and accuracy for use in identification, crime investigation, immigration control, security ... ... A research team led by ...
(Date:3/29/2017)... -- higi, the health IT company that operates the largest ... , today announced a Series B investment from BlueCross ... new investment and acquisition accelerates higi,s strategy to create ... health activities through the collection and workflow integration of ... and secures data today on behalf of over 36 ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... ... October 12, 2017 , ... RPS ... clinical study that demonstrates the accuracy of the FebriDx® test, a commercially-ready, ... acute bacterial and viral respiratory tract infections by testing the body’s immune ...
(Date:10/11/2017)... ... October 11, 2017 , ... The CRISPR-Cas9 ... enabling overexpression experiments and avoiding the use of exogenous expression plasmids. The simplicity ... for performing systematic gain-of-function studies. , This complement to loss-of-function studies, such ...
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017 /PRNewswire/ ... London (ICR) and University of ... tool to risk-stratify patients with multiple myeloma (MM), in a ... . The University of Leeds is ... Myeloma UK, and ICR will perform the testing services to ...
(Date:10/10/2017)... CA (PRWEB) , ... October ... ... a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today ... of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration ...
Breaking Biology Technology: